Small-Cell Lung Cancer - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Small-Cell Lung Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 47, 33, 2, 36 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Small-Cell Lung Cancer - Overview
  3. Small-Cell Lung Cancer - Therapeutics Development
  4. Small-Cell Lung Cancer - Therapeutics Assessment
  5. Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
  6. Small-Cell Lung Cancer - Drug Profiles
  7. Small-Cell Lung Cancer - Dormant Projects
  8. Small-Cell Lung Cancer - Discontinued Products
  9. Small-Cell Lung Cancer - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/jwl8bq/smallcell_lung?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs